172 related articles for article (PubMed ID: 36921315)
1. Loss of LGR5 through Therapy-induced Downregulation or Gene Ablation Is Associated with Resistance and Enhanced MET-STAT3 Signaling in Colorectal Cancer Cells.
Posey TA; Jacob J; Parkhurst A; Subramanian S; Francisco LE; Liang Z; Carmon KS
Mol Cancer Ther; 2023 May; 22(5):667-678. PubMed ID: 36921315
[TBL] [Abstract][Full Text] [Related]
2. GPR56 Drives Colorectal Tumor Growth and Promotes Drug Resistance through Upregulation of MDR1 Expression via a RhoA-Mediated Mechanism.
Zhang S; Chatterjee T; Godoy C; Wu L; Liu QJ; Carmon KS
Mol Cancer Res; 2019 Nov; 17(11):2196-2207. PubMed ID: 31444231
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
[TBL] [Abstract][Full Text] [Related]
4. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
[TBL] [Abstract][Full Text] [Related]
6. LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer.
Cao HZ; Liu XF; Yang WT; Chen Q; Zheng PS
Cell Death Dis; 2017 Sep; 8(9):e3039. PubMed ID: 28880275
[TBL] [Abstract][Full Text] [Related]
7. Lgr5 Methylation in Cancer Stem Cell Differentiation and Prognosis-Prediction in Colorectal Cancer.
Su S; Hong F; Liang Y; Zhou J; Liang Y; Chen K; Wang X; Wang Z; Wang Z; Chang C; Han W; Gong W; Qin H; Jiang B; Xiong H; Peng L
PLoS One; 2015; 10(11):e0143513. PubMed ID: 26599100
[TBL] [Abstract][Full Text] [Related]
8. LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs.
Al-Kharusi MR; Smartt HJ; Greenhough A; Collard TJ; Emery ED; Williams AC; Paraskeva C
Carcinogenesis; 2013 May; 34(5):1150-7. PubMed ID: 23349017
[TBL] [Abstract][Full Text] [Related]
9. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence.
Gong X; Azhdarinia A; Ghosh SC; Xiong W; An Z; Liu Q; Carmon KS
Mol Cancer Ther; 2016 Jul; 15(7):1580-90. PubMed ID: 27207778
[TBL] [Abstract][Full Text] [Related]
10. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
11. Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway.
Mao X; Zhang X; Zheng X; Chen Y; Xuan Z; Huang P
J Nat Med; 2021 Jun; 75(3):590-601. PubMed ID: 33713277
[TBL] [Abstract][Full Text] [Related]
12. LGR5 regulates survival through mitochondria-mediated apoptosis and by targeting the Wnt/β-catenin signaling pathway in colorectal cancer cells.
Hsu HC; Liu YS; Tseng KC; Tan BC; Chen SJ; Chen HC
Cell Signal; 2014 Nov; 26(11):2333-42. PubMed ID: 25025569
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
[TBL] [Abstract][Full Text] [Related]
14. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer.
Leng Z; Xia Q; Chen J; Li Y; Xu J; Zhao E; Zheng H; Ai W; Dong J
Cell Physiol Biochem; 2018; 46(2):860-872. PubMed ID: 29627827
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells.
Kemper K; Prasetyanti PR; De Lau W; Rodermond H; Clevers H; Medema JP
Stem Cells; 2012 Nov; 30(11):2378-86. PubMed ID: 22969042
[TBL] [Abstract][Full Text] [Related]
16. LGR5 induces β-catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma.
Kawasaki K; Kuboki S; Furukawa K; Takayashiki T; Takano S; Ohtsuka M
Liver Int; 2021 Apr; 41(4):865-881. PubMed ID: 33249719
[TBL] [Abstract][Full Text] [Related]
17. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum.
Takahashi H; Ishii H; Nishida N; Takemasa I; Mizushima T; Ikeda M; Yokobori T; Mimori K; Yamamoto H; Sekimoto M; Doki Y; Mori M
Ann Surg Oncol; 2011 Apr; 18(4):1166-74. PubMed ID: 21125339
[TBL] [Abstract][Full Text] [Related]
18. CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.
Hsu HC; Liu YS; Tseng KC; Yang TS; Yeh CY; You JF; Hung HY; Chen SJ; Chen HC
J Cancer Res Clin Oncol; 2015 Jan; 141(1):11-21. PubMed ID: 25060070
[TBL] [Abstract][Full Text] [Related]
19. LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity.
Morgan RG; Mortensson E; Legge DN; Gupta B; Collard TJ; Greenhough A; Williams AC
Br J Cancer; 2018 Feb; 118(4):558-565. PubMed ID: 29149105
[TBL] [Abstract][Full Text] [Related]
20. SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.
Planutis AK; Holcombe RF; Planoutene MV; Planoutis KS
Anticancer Drugs; 2015 Oct; 26(9):942-7. PubMed ID: 26196680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
